Tarle M, Kovacić K, Kastelan M
Nuclear Medicine and Oncology Clinic, University Hospital Sestre Milosrdnice, Zagreb, Croatia.
Anticancer Res. 1993 Jan-Feb;13(1):215-8.
Tissue polypeptide specific antigen (TPS) is a new tumor proliferation serotest marker. The respective radioimmunodetective procedure is based on the application of monoclonal antibodies raised against one the principle epitopes of tissue polypeptide antigen (TPA). TPS is useful tool for the identification of proliferative epithelial cells and is negative in all non-epithelial tissues such as lymph nodes, bone marrow, carcino-sarcomic and neuroendocrine prostatic tumors. In previous studies we have shown the clinical usefulness of this serotest in serial measurements during prostate cancer monitoring. In this study serum prostatic specific antigen (PSA) concentrations and natural killer (NK) cell activity data were compared with serum TPS values in a wide spectrum of prostate cancer condition (99 patients), benign prostatic hypertrophy (BPH, 40 patients), atypical prostate (12 subjects) and in 8 healthy men. Measured parameters reflect different aspects of the disease. Blood PSA concentrations and TPS serotest values were found to denote the status of disseminated prostate cancer with nearly equal significance, while PSA appears to be a more appropriate tumor marker in early stages of the disease. In atypical prostate a nonsignificant elevation of both PSA and TPA values were recorded when compared with BPH. In parallel, a pronounced and sharp drop in NK activity data was assessed resembling closely respective data in progressive Stage D2 patients. TPS serotest clearly detects cancer progression in treated and untreated patients (P < 0.01) while being less efficient in distinguishing between tumor stabilization and partial remission (p > 0.05). In this respect NK activity data serve as a sensitive probe for the presence of epithelial tumor cells in the circulation even during stabilization of the disease. According to the reported results we advocate the application of the TPS serotest as a useful addition in monitoring progressive patients with advanced prostatic carcinoma.
组织多肽特异性抗原（TPS）是一种新型肿瘤增殖血清学检测标志物。其各自的放射免疫检测方法基于针对组织多肽抗原（TPA）的一个主要表位产生的单克隆抗体的应用。TPS是鉴定增殖性上皮细胞的有用工具，在所有非上皮组织如淋巴结、骨髓、癌肉瘤和神经内分泌性前列腺肿瘤中均为阴性。在先前的研究中，我们已经表明这种血清学检测在前列腺癌监测的系列测量中的临床实用性。在本研究中，比较了广泛的前列腺癌病情（99例患者）、良性前列腺增生（BPH，40例患者）、非典型前列腺（12例受试者）以及8名健康男性的血清前列腺特异性抗原（PSA）浓度和自然杀伤（NK）细胞活性数据与血清TPS值。所测量的参数反映了疾病的不同方面。发现血液PSA浓度和TPS血清学检测值在表示播散性前列腺癌状态方面具有几乎同等的意义，而PSA在疾病早期似乎是一种更合适的肿瘤标志物。与BPH相比，非典型前列腺中PSA和TPA值均有非显著性升高。同时，评估发现NK活性数据有明显且急剧的下降，与进展期D2患者的相应数据非常相似。TPS血清学检测能清楚地检测出治疗和未治疗患者的癌症进展（P < 0.01），而在区分肿瘤稳定和部分缓解方面效率较低（P > 0.05）。在这方面，即使在疾病稳定期间，NK活性数据也可作为循环中上皮肿瘤细胞存在的敏感探针。根据报告的结果，我们主张应用TPS血清学检测作为监测晚期前列腺癌进展患者的一种有用补充方法。
